Galvanize Therapeutics Raises $130M for Pulsed Field Ablation Tech

It recently gained FDA clearance for its Aliya EX Generator.

Colorscribe medical device with touchscreen display on purple background with cables
Galvanize Therapeutics

Galvanize Therapeutics announced the closing of a $130 million financing round to advance its pulsed electric field (PEF) ablation technology.  

Over the past year, Galvanize said it has built commercial, clinical and technological momentum. Key milestones include FDA clearance and commercial launch of the next-generation Aliya EX Generator, expanding physician adoption of Aliya PEF technology, and surpassing 4,000 procedures performed. The company has also strengthened its clinical evidence program, enrolling more than 300 patients in its PROPEL registry and contributing to a growing body of scientific literature that includes over 40 peer-reviewed publications exploring PEF mechanisms of action, clinical outcomes, and potential applications across oncology and chronic disease.

"This financing marks an important inflection point for Galvanize," said Doug Godshall, Chairman and Chief Executive Officer of Galvanize Therapeutics. "We've built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution, and an expanding body of clinical evidence. This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease. We're grateful for the continued confidence of our investors as we enter this next phase of growth."

Proceeds from the financing will support continued commercial expansion of Aliya, investment in clinical evidence generation, advancement of RheOx therapy for chronic bronchitis, and development of next-generation PEF products and platforms.

"We have followed Galvanize's progress closely over the years and are thrilled to back the company as it enters its next phase of growth," said Garheng Kong, MD, PhD, Founder and Managing Partner of HealthQuest Capital. "Galvanize has built a differentiated PEF platform with the potential to meaningfully advance care in interventional oncology and pulmonology. We are excited to partner with the exceptional team as they expand the reach and impact of their innovative technology."

In connection with the financing, Kong will join the Galvanize Board of Directors.

More in Surgical